Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 9/20 | 0.73 |
| ▸ | SLC40A1 | Q9NP59 | 9/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.67 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.67 |
| ▸ | NFKBIA | P25963 | 2/20 | 0.67 |
| ▸ | G6PD | P11413 | 1/20 | 0.67 |
| ▸ | METAP2 | P50579 | 1/20 | 0.67 |
| ▸ | METAP1 | P53582 | 1/20 | 0.67 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.67 |
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | MITF | O75030 | 1/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7193613 | 0.85 | SLC40A1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL13485932 | 0.81 | SLC40A1 (0.93) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL442367 | 0.81 | SLC40A1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL30925586 | 0.80 | SLC40A1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL29799662 | 0.80 | TDP1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL13485950 | 0.80 | SLC40A1 (0.80) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL6981081 | 0.80 | SLC40A1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL13638616 | 0.80 | SLC40A1 (0.76) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL3825367 | 0.80 | TDP1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA | |
| SCHEMBL6978005 | 0.80 | GLO1 (1.00) | GLO1SLC40A1TDP1AGTR1NFKBIA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8785450-B2 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | AGIOS PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183311-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | GLO1 1916/4885SLC40A1 1730/4885TDP1 2573/4885 |
| US-20100331307-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | GLO1 1916/4885SLC40A1 1730/4885TDP1 2573/4885 |
| US-20140323467-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | PDK1, PDK2, PDK3 | GLO1 1916/4885SLC40A1 1730/4885TDP1 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.